Enhancing Efficiency and Strategy of Investor Outreach

By Cameron Hurlburt, Manager of Business Development – West Coast (US), LSN

Life Science Nation (LSN) has implemented a new pricing model for our Investor and Licensing Partner Database. This database contains 3K+ investor firms, with specific interests in the early-stage life science sector, across 10 categories of investors* and licensing partners, including 10K+ contacts. Searches can be executed through specific filters including but not limited to, sector, subsector, indication, and phase of development. The information presented in the database is obtained directly from each company through 1:1 interviews with investor research analysts at LSN and updated regularly. This is a valuable resource for companies looking to establish their Global Target List and execute their fundraising journey.

*10 categories of investors:

Angel Groups
Corporate Venture Capital
Endowments/Foundations
Family Office/Private Wealth Funds
Government Organizations

Hedge Funds
Institutional Alternative Investors
Large Pharma/ Biotech Companies
Private Equity
Venture Capital

The prior pricing model was $4.5K for 6 months or $7K for 1 year. Since most companies that wish to utilize our database are early-stage and pre-revenue, LSN aimed to transition the hefty up-front cost to a monthly, lower-cost plan. Our new subscription options are shown below:

Standard:

$300/month or $3K/year up-front
Minimum 6 months commitment

Premier (Recommended):

$500/month or $5K/year up-front
Includes 50% off ALL RESI Registrations for the duration of the subscription (excludes IPC)
Minimum 6 months commitment

To learn more about this database, please contact your Business Development Manager at Life Science Nation and we would be happy to walk you through the database and help answer any questions or concerns you may have!

Life Science Nation Business Development Team
International	East Coast (USA) & China	Midwest (USA) & Canada	West Coast (USA)

Greg Mannix Vice President International Business Development Book a Meeting Email Me	Candice He VP, Business Development & Global Investment Strategist Book a Meeting Email Me	Antoinette Lowre Manager of Business Development Book a Meeting Email Me	Cameron Hurlburt Manager of Business Development Book a Meeting Email Me

Comments Leave a Comment
Categories Redefining Every Stage Investments (RESI)

Hot Mandates

Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease

The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases

A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA

The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health

A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]

Search